Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

31) AMPLITUDE-O results (2021): That secondary composite renal outcome (UACR >300, UACR ≥30% increase from baseline, ESRD or death from any cause ) favored efpeglenatide 🔓 https://t.co/Jz5inIwWEn https://t.co/vvWfyJLaWw

@DachsClinic 最新のGLP-1RAの比較試験で、SGLT2iがベースラインに入った人が含まれてるものがあります。 SGLT2iを含む含まないに関わらず、同様の傾向であったとのことです(URLの論文のfigure2の下の方です)。 https://t.co/fZ4gEYaM9l

Gerstein et al. examined the effect of administrating weekly injections of efpeglenatide on cardiovascular and renal outcomes in patients with type 2 diabetes. Read more here: https://t.co/EGiYGMYzBN

@mikejohansenmd @hagilani While I do still assume this until proven otherwise for now, my preliminary reading of AMPLITUDE-O makes me wonder what the effect size will be (obviously this trial not really setup to answer the question): https://t.co/qm0Hz4WF

RT @ckd_ce: 31) AMPLITUDE-O results (2021): That secondary composite renal outcome (UACR >300, UACR ≥30% increase from baseline, ESRD or de…

31) AMPLITUDE-O results (2021): That secondary composite renal outcome (UACR >300, UACR ≥30% increase from baseline, ESRD or death from any cause) favored efpeglenatide 🔓 https://t.co/Jz5inIwWEn https://t.co/0fpwcWPkUz

RT @cardiomet_CE: 20) What's new with #GLP-1ra's in CKD? 📍new data & meta-analysis (AMPLITUDE-O,🔓https://t.co/WJly4rOQJj) 📍recommendation r…

20) What's new with #GLP-1ra's in CKD? 📍new data & meta-analysis (AMPLITUDE-O,🔓https://t.co/WJly4rOQJj) 📍recommendation remains: For glycemic management after metformin & SGLT2i 📍New weight-loss practice point added: "GLP-1ra are effective agents f

RT @sophia_kidney: Secondary renal composite outcomes in #AMPLITUDEO trial favored #GLP1agonist efpeglenatide when compared to placebo

Secondary renal composite outcomes in #AMPLITUDEO trial favored #GLP1agonist efpeglenatide when compared to placebo

RT @ckd_ce: 32) There are *more recent data* from the #AMPLITUDE-O #RCT of CV & renal outcomes with #efpeglenatide vs placebo in T2D. ✔️out…

33) AMPLITUDE-O results: That secondary composite renal outcome favored efpeglenatide; 353 events occurred in efpeglenatide vs 250 in patients on placebo HR 0.6 (95% CI 0.57-0.79, p <0.001) https://t.co/Jz5inIwWEn https://t.co/8CWZWFtVoG

32) There are *more recent data* from the #AMPLITUDE-O #RCT of CV & renal outcomes with #efpeglenatide vs placebo in T2D. ✔️out the secondary composite outcome: UACR >300, UACR ≥30% increase from baseline, ESRD or death from any cause https://t.co/J

#NephGR today #NephFellow Dr. Cassidy Onukwuli talking GLP1-RAs and kidney outcomes https://t.co/pUzLZ4MDAf https://t.co/SPUyeDwhSN

RT @MacDeptMed: RECENT PUBLICATION: Cardiovascular & Renal Outcomes with Efpeglenatide in Type2 #Diabetes https://t.co/qe4VG1TSWg. Led by D…

RT @MacDeptMed: RECENT PUBLICATION: Cardiovascular & Renal Outcomes with Efpeglenatide in Type2 #Diabetes https://t.co/qe4VG1TSWg. Led by D…

RT @MacDeptMed: RECENT PUBLICATION: Cardiovascular & Renal Outcomes with Efpeglenatide in Type2 #Diabetes https://t.co/qe4VG1TSWg. Led by D…

RT @MacDeptMed: RECENT PUBLICATION: Cardiovascular & Renal Outcomes with Efpeglenatide in Type2 #Diabetes https://t.co/qe4VG1TSWg. Led by D…

RT @MacDeptMed: RECENT PUBLICATION: Cardiovascular & Renal Outcomes with Efpeglenatide in Type2 #Diabetes https://t.co/qe4VG1TSWg. Led by D…

RECENT PUBLICATION: Cardiovascular & Renal Outcomes with Efpeglenatide in Type2 #Diabetes https://t.co/qe4VG1TSWg. Led by Dr. #HertzelGerstein, it was named one of the top #heartdisease and #stroke advances in 2021 by @American_Heart #MedEd @McMasterU

RT @DiabetoPitie: Protection cardiovasculaire #MACE et rénale #CKD sous #Efpeglenatide indépendante des #SGLT2 inhibiteurs. Randomisation s…

Protection cardiovasculaire #MACE et rénale #CKD sous #Efpeglenatide indépendante des #SGLT2 inhibiteurs. Randomisation stratifiée sur l'utilisation des iSGLT2. #EBM association des #GLP1 analogues + #SGLT2 inhibiteurs dans #DT2 + haut risque CV! https://t

efpeglenatideは、韓国のHanmi Pharmaceutical社（韓美薬品）が創薬しサノフィ社に導出したGLP-1受容体作動薬である。 https://t.co/IjFNcu0x5q

RT @KSusztak: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | ⁦@NEJM⁩ https://t.co/qtUb07ypXf

RT @KSusztak: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | ⁦@NEJM⁩ https://t.co/qtUb07ypXf

RT @UNCKidney: ‼️ Another win for cardio-renal medicine! An exendin-based GLP1ra reduces MACE and composite renal outcome. ➕Weekly dosing…

RT @UNCKidney: ‼️ Another win for cardio-renal medicine! An exendin-based GLP1ra reduces MACE and composite renal outcome. ➕Weekly dosing…

RT @UNCKidney: ‼️ Another win for cardio-renal medicine! An exendin-based GLP1ra reduces MACE and composite renal outcome. ➕Weekly dosing…

RT @KSusztak: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | ⁦@NEJM⁩ https://t.co/qtUb07ypXf

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | ⁦@NEJM⁩ https://t.co/qtUb07ypXf

‼️ Another win for cardio-renal medicine! An exendin-based GLP1ra reduces MACE and composite renal outcome. ➕Weekly dosing ➕Signal for fewer "reduced renal function" events ➖More treatment stoppage in GLP1ra arm, mainly due to GI side effects https://t.c

این فیلم رو امروز در یوتیوب بارگذاری کردم

درمان جدید دیابت efpeglenatide منبع: https://t.co/etSsJmm91K https://t.co/oqDGoQ5OlA via @YouTube

(NEJM) Resultados cardiovasculares y renales con efpeglenatida en la diabetes tipo 2. https://t.co/sj3oeFB28w. Via @Sefap_FAP #diabetes

Resultados cardiovasculares y renales con efpeglenatida en la diabetes tipo 2 https://t.co/9aNmilMbkm

RT @Sefap_FAP: (NEJM) Efpeglenatida y resultados cardiovasculares en pacientes con diabetes tipo 2 https://t.co/URQsf8gzZN https://t.co/OrP…

(NEJM) Efpeglenatida y resultados cardiovasculares en pacientes con diabetes tipo 2 https://t.co/URQsf8gzZN https://t.co/OrPgq6CS4R

RT @CastlDalmunzie: In this trial involving participants with #T2D who had either a history of #CVD or current #kidneydisease ➕ at least 1…

RT @CastlDalmunzie: In this trial involving participants with #T2D who had either a history of #CVD or current #kidneydisease ➕ at least 1…

In this trial involving participants with #T2D who had either a history of #CVD or current #kidneydisease ➕ at least 1 other CV risk factor, the risk of CV events was ⏬ among those who is weekly #efpeglenatide 💉 than those is in placebo group . https://t.c

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/uXObu6dTU2

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

@htTweets @gernalist https://t.co/SL7FhHQcUj

@RemaNagarajan @thewire_in https://t.co/SL7FhHQcUj

@ramyakannan @frontlinepbs https://t.co/SL7FhHQcUj

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

RT @SehsuvarErturk: Bugün #NEJM #Kardiyovaskülerhastalık ya da #kronikböbrekhastalığı olan Tip 2 #diyabet'lilerde #GLP1ra #efpeglenatide'in…

RT @ValleAlfonso: @nejm 📂 https://t.co/R7S7zooYL8

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM #Cardiotwitter #Medtwitter #Renal #CardioRenal #CardioMetabolic ⁦@CMClinicUK⁩ ⁦@EASDnews⁩ ⁦@NEJM⁩ https://t.co/liDskESlws

32% decrease in composite renal outcome together with CV benefits with Efpeglenatide | NEJM https://t.co/hVleJ4AqJX

Ok we’re back to our regularly scheduled programming. New GLP-1 agonist HR 0.68 for microalbuminuria or decreased renal function compared to placebo in #T2DM #KidneyDisease Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM ht

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

Cardiovascular and #RenalOutcomes with #Efpeglenatide in Type 2 Diabetes @NEJM https://t.co/Z6QseKnpPi https://t.co/dQPeBCzFk6

RT @ValleAlfonso: @nejm 📂 https://t.co/R7S7zooYL8

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

Another victorious battle in the war against cardiovascular complications of diabetes mellitus, thanks to the exendin-based GLP-1 receptor agonist, efpeglenatide! https://t.co/vmP93FfT8b https://t.co/IDMcwRv9As

RT @SeguraCardio: 📁https://t.co/OGZwNRDrlH

📁https://t.co/OGZwNRDrlH

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/oIfqJ7fkKt

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes #HelsinkiHealth #tutkimus #tiede https://t.co/YMrvwxVOMw

Bugün #NEJM #Kardiyovaskülerhastalık ya da #kronikböbrekhastalığı olan Tip 2 #diyabet'lilerde #GLP1ra #efpeglenatide'in kalp-damar ve böbrek sonuçlarına etkileri. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes https://t.co/lt68BH28

@nejm 📂 https://t.co/R7S7zooYL8

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

RT @HanCardiomd: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces…

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/42Uaim5ShB

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes SC efpeglenatide at a dose of 4 or 6 mg reduces the risk of MACE and renal events among persons with T2DM and either a history of CVD or current kidney disease https://t.co/0TogNovp

RT @DrKarlNadolsky: https://t.co/b2xKQBJvOj https://t.co/jXneFhyJG9

RT @BeetSchu: 아마도 조만간 GLP1 agonist와 같은 주 1회 투여 형태의 주사제가 당뇨병 혹은 심혈관/신질환 위험성 있는 환자 관리의 주된 형태가 될지도 모르겠다. https://t.co/BBzNEVdhAA

MeToo for efpeglenatide for MACE outcomes in Type 2 Diabetes. But why are these trials still reaching NEJM-level pubs? https://t.co/ELZz4sdyjU

아마도 조만간 GLP1 agonist와 같은 주 1회 투여 형태의 주사제가 당뇨병 혹은 심혈관/신질환 위험성 있는 환자 관리의 주된 형태가 될지도 모르겠다. https://t.co/BBzNEVdhAA

https://t.co/b2xKQBJvOj https://t.co/jXneFhyJG9

RT @JamesNovakNeph: Outcomes move in the right direction, but not a kidney disease trial in the spirit of CREDENCE. Baseline eGFR 72.4, bas…

Outcomes move in the right direction, but not a kidney disease trial in the spirit of CREDENCE. Baseline eGFR 72.4, baseline UACR 28.3. #GLP-1 #SGLT2 ⁦@NEJM⁩ https://t.co/7HDDIi4EOt

RT @RahulDBarmanray: Another GLP-1RA (efpeglenatide) shows improvement in 3-point MACE with an impressive HR of 0.73. Even more impressiv…

Another GLP-1RA (efpeglenatide) shows improvement in 3-point MACE with an impressive HR of 0.73. Even more impressive, it's the first exendin-based GLP-1RA to show a mortality benefit! #diabetes #Endotwitter #medtwitter https://t.co/JyFbXFG7oe

RT @CristobMorales: https://t.co/lg5OPcg2He SOTAGLIFLOZINA y EFPEGLENATIDE https://t.co/YzHbcqyxCM #ADA2021 2 moléculas que desde la canter…

Publication of the Month: #Cardiovascular & Renal Outcomes with Efpeglenatide in Type2 #diabetes. Finding: The risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide than those who received plac

RT @cardiomet_CE: And there you have it! Another rundown of a key presentation from #ADA2021 If that's not enough, have a read of the paper…

And there you have it! Another rundown of a key presentation from #ADA2021 If that's not enough, have a read of the paper 👇https://t.co/WJly4s6rAR

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/dZB8sfRPDJ

RT @RpratleyMD: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM. Exciting news from the latest GLP-1RA CVOT…

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes https://t.co/3fuhIZoZM5 https://t.co/IQihrQPerV

New post in Development of Pharmacy Channel: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes https://t.co/IDpoIJaHiq https://t.co/K7OrMmutgO

AMPLITUDE-O trial: In Pts. with DM2 (A1C>7%) and CVD or CKD (eGFR 25-60 mL/min) + at least 1 CV RF, efpeglenatide 4-6 mg SC weekly ⬇️MACE (ARR 2.2%) and secondary renal outcome (ARR 5.4%) vs. placebo at median 1.81 years. ⬆️GI effects with efpeglenatide

RT @R_Campuzano_R: Siguen las buenas noticias: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/…

RT @KSusztak: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | ⁦@NEJM⁩ https://t.co/qtUb07gP5H

Efpeglenatide joins the secondary prevention club. HR 0.73 (CI 0.58 to 0.92) for MACE https://t.co/ELZz4sdyjU

AMPLITUDE-O study: Efpeglenatide (GLP1RA) reduces cardiovascular events in people with type 2 diabetes by 27%. Benefit was independent of SGLT2 inhibitors. Exendin base of efpeg suggests that CV benefits of GLP1RAs are not restricted to human GLP1 analogs

"In this trial involving participants with type 2 DM who had a history of CVD or current kidney disease plus at least one other CV risk factor, the risk of CV events was lower among those who received efpeglenatide than among those who received placebo" ht

RT @RpratleyMD: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM. Exciting news from the latest GLP-1RA CVOT…

RT @PabloPerezMar16: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/6SK5RNsqYN

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | @NEJM https://t.co/gZOg52rHGd Another potential candidate for the management of diabetic kidney disease? Wait..How do you pronounce that again?

RT @FernandoCiveir1: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/Bg5YmvnTnM

Neue Studie zu #GLP1-Agonist bei Typ 2 Diabetes, #Efpeglenatid, Exendin-basiert=langwirksam. Hochrisikokollektiv, knappes Drittel MACE-Reduktion. 46 Patienten 1,8 J behandeln = 1 Tod/MI/Stroke verhindern. Ev. on top of SGLT2i (!), aber kleine Subgruppe. ht

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/6SK5RNsqYN

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | NEJM https://t.co/OYciPZj9uc